SCHEMBL21884109

SCHEMBL21884109

C[C@@H](CO)n1cnc2c(NCCc3c[nH]c4ccccc34)nc(-c3cncc(P)c3)nc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCNE2 O96020 1/20 0.48
▸ CCNE1 P24864 1/20 0.48
▸ CDK2 P24941 1/20 0.48
▸ GBA1 P04062 1/20 0.48
▸ CYP1A2 P05177 7/20 0.42
▸ CYP3A4 P08684 7/20 0.42
▸ CYP2D6 P10635 7/20 0.42
▸ CYP2C19 P33261 7/20 0.42
▸ CYP2C9 P11712 6/20 0.42
▸ MEN1 O00255 5/20 0.42
▸ KMT2A Q03164 5/20 0.42
▸ LMNA P02545 5/20 0.42
▸ USP2 O75604 5/20 0.42
▸ ALDH1A1 P00352 4/20 0.42
▸ TSHR P16473 3/20 0.42
▸ CLK4 Q9HAZ1 3/20 0.42
▸ HSD17B10 Q99714 3/20 0.42
▸ TP53 P04637 5/20 0.40
▸ MAPK1 P28482 5/20 0.40
▸ MAPT P10636 4/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30130604 0.92 CCNE2 (0.48) CCNE2CCNE1CDK2GBA1CYP1A2
SCHEMBL30476574 0.92 CCNE2 (0.48) CCNE2CCNE1CDK2GBA1CYP1A2
SCHEMBL2317462 0.92 CCNE2 (0.48) CCNE2CCNE1CDK2GBA1CYP1A2
SCHEMBL30013436 0.92 CCNE2 (0.48) CCNE2CCNE1CDK2GBA1CYP1A2
SCHEMBL2317472 0.92 CCNE2 (0.48) CCNE2CCNE1CDK2GBA1CYP1A2
SCHEMBL2359481 0.92 CCNE2 (0.48) CCNE2CCNE1CDK2GBA1CYP1A2
SCHEMBL20895831 0.92 CCNE2 (0.48) CCNE2CCNE1CDK2GBA1CYP1A2
SCHEMBL20895830 0.92 CCNE2 (0.48) CCNE2CCNE1CDK2GBA1CYP1A2
SCHEMBL2359766 0.86 CCNE2 (0.49) CCNE2CCNE1CDK2GBA1CYP1A2
SCHEMBL2358529 0.86 CCNE2 (0.49) CCNE2CCNE1CDK2GBA1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200102561-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES INTELLIA THERAPEUTICS, INC. 2020-04-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200102561-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES HBG2, HBB, HBG1 CCNE2 4335/4885CCNE1 4330/4885CDK2 4086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback